[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"microplastics\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:microplastics":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,45,74,106,151],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":21,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100615361","microplastics-and-nanoplastics-in-patients-with-chronic-coronary-syndromes-100615361",false,"NCT07291609","Microplastics and Nanoplastics in Patients With Chronic Coronary Syndromes","CCS-Plastics","Inclusion Criteria:\n\nALL the following:\n\n1. Age \\> 18 years old;\n2. Suspected or known chronic coronary syndromes undergoing coronary CT angiography;\n3. Clinical indication to invasive coronary angiography;\n4. Able to give informed consent.\n\nExclusion Criteria:\n\n1. Coronary CT angiography not available;\n2. Poor quality CCTA;\n3. Absence of native coronary stenosis \\>=50% at CCTA;\n4. Contraindications to invasive coronary angiography and percutaneous coronary intervention\n5. Life expectancy \\\u003C 1 year due to non-cardiac pathology","ALL","18 Years",{"count":19,"type":20},120,"ESTIMATED","3 Years","OBSERVATIONAL","The CCS-plastics is an investigator-initiated, prospective, multicenter study of patients undergoing coronary CT angiography (CCTA) for suspected or known chronic coronary syndromes (CCS) referred to invasive coronary angiography for clinical indication. Patients identified as eligible for the protocol will be asked for written consent to participate in the study. The patients' dossiers will be uploaded and transmitted to the core laboratory for analysis. The routine management of the CCS patients will not be affected and all patients will be managed according to current standards. Invasive coronary angiography and coronary blood samples will be performed following the current standards, guidelines, and indications. During invasive coronary angiography, coronary blood samples will be collected per standard of care and sent to a centralized, specialized core laboratory for MNPs and biomarkers analysis. The central core lab for MNPs analyses will be the University of Campania Luigi Vanvitelli, Naples, Italy. The identification, quantification (concentration, mcg\u002Fml), and typing of plastic particles will be performed in each tube for each patient, using pyrolysis-gas chromatography-mass spectrometry (Py-GC\u002FMS) and laser direct infrared (LDIR) spectroscopy. The CCTA will be centrally analyzed by Centro Cardiologico Monzino to evaluate qualitative and quantitative plaque features. Patients will be followed clinically at 1 and 3 years per standard of care.",[25,26,27,28,29,30,31],"Chronic Coronary Syndrome","Microplastics","Nanoplastics","Coronary Artery Disease","Coronary Plaque","Computed Tomography","Pollution Exposure","RECRUITING","2026-06-06",{"date":35,"type":36},"2026-06-09","ACTUAL",{"date":38,"type":36},"2025-01-01",{"date":40,"type":20},"2029-12-31",{"name":42,"class":43},"Azienda Ospedaliera \"Sant'Andrea\"","OTHER",6,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":4,"eligibilityCriteria":51,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":52,"enrollmentInfo":53,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":55,"conditions":56,"keywords":61,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":73},"100614499","microplastics-cirrhosis-and-portal-hypertension-100614499","NCT07280390","Microplastics, Cirrhosis and Portal Hypertension","The Impact of Microplastics and Nanoplastics on Liver Health and Cardiovascular Diseases in India","Inclusion Criteria:\n\n* Age range of 18-70 years\n* Cirrhosis, as diagnosed by histology or clinical, laboratory and USG findings.\n* Undergoing elective surgery or liver transplantation\n\nExclusion Criteria:\n\n* • Hepatocellular carcinoma\n\n  * Pregnancy or lactation\n  * Patients with HIV or retroviral therapy\n  * Prior liver interventions like locoregional therapy, presence of HCC, prior abdominal surgery","70 Years",{"count":54,"type":20},30,"Cirrhosis and portal hypertension are associated with an hyperdynamic circulation and hepatic inflammation, leading to complications like ascites, variceal bleeding, acute kidney injury, and higher infection risk. Microplastics (MPs) are a global plastic pollution issue, and studies have found plastic MPs or nanoparticles (NPs) contaminating human, animal and environmental ecosystems.It has been noted that the accumulation of MPs increases with a reduction in size of the plastic particle. MPs are categorized into primary particles such as manufactured plastics including pellets and cosmetic microbeads and secondary particles which originate from mechanical and ultraviolet disruption of large plastic particles. MPs can be ingested via food or beverages, especially plastic packaged comestibles or inhaled as environmental pollutants. Contamination of medications such as antibiotics, intravenous fluids, albumin and medical devices is another source of exposure to microplastics in patients with chronic liver disease (CLD)In particular exposure to endoscopic interventions, liver biopsy, and invasive procedures such as paracentesis and interventional radiology procedures can lead to plastic exposure and deposition of MPs in the liver and other tissues in patients with cirrhosis. It may be hypothesized that these may contribute to hepatic inflammation and progression of cirrhosis and portal hypertension.\n\nGlobally, there is new research on the influence of MPs on the environment, plant and animal ecosystems and human health.\n\nPolystyrene (PS) microspheres that concentrate in the liver, intestine and the kidneys of mammals disrupt lipid and energy metabolism, impair mucus secretion, and alter the microbiome. Therefore, studies are required to assess how and to what extent, MPs impact human health, and affect chronic diseases like cirrhosis and reduce longevity.\n\nThe study investigators will assess the presence of MPs in the liver, kidneys and intestine of patients with liver cirrhosis and compare it with those without underlying liver disease and determine the impact on portal hypertension and fibrosis, and cardiovascular and metabolic function.",[57,26,58,27,59,60],"Cirrhosis","Portal Hypertension Related to Cirrhosis","Pollution","Cirrhosis and Chronic Liver Disease",[26,27,62,57,63],"Plastic pollution","Portal hypertension","2026-05-13",{"date":66,"type":36},"2026-05-15",{"date":68,"type":36},"2026-05-01",{"date":70,"type":20},"2027-02-25",{"name":72,"class":43},"Post Graduate Institute of Medical Education and Research, Chandigarh",2,{"id":75,"slug":76,"hasResults":11,"nctId":77,"briefTitle":78,"officialTitle":78,"acronym":79,"eligibilityCriteria":80,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":81,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":83,"conditions":84,"keywords":86,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":97,"lastUpdatePostDateStruct":98,"startDateStruct":100,"completionDateStruct":102,"leadSponsor":104,"locationsCount":105},"100590254","microplastics-and-nanoplastics-mnps-in-patients-with-st-elevation-myocardial-infarction-stemi-100590254","NCT06965023","Microplastics and Nanoplastics (MNPs) in Patients With ST-elevation Myocardial Infarction (STEMI)","STEMI-Plastics","Inclusion Criteria:\n\nAll the following inclusion criteria should be fulfilled:\n\n1. Age \\> 18 years old;\n2. STEMI undergoing urgent invasive coronary angiography;\n3. Acute thrombotic coronary occlusion\u002Fsub-occlusion (TIMI 0\u002F1);\n4. Clinical indication to thromboaspiration;\n5. Able to give informed consent.\n\nExclusion Criteria:\n\n1. Contraindications to percutaneous coronary intervention;\n2. Hemodynamic instability or cardiogenic shock;\n3. End-stage chronic kidney disease;\n4. Life expectancy \\\u003C 1 year due to non-cardiac pathology.",{"count":82,"type":20},130,"Air pollution and microplastics pose major public health threats. Emerging data have shown that micro- and nanoplastics (MNPs) are ubiquitous environmental pollutants accumulating in human tissues, triggering inflammation and prothrombotic state. This study will investigate the presence and burden of MNPs within coronary thrombi\u002Fthromboaspirate of patients presenting with ST segment elevation acute myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention and their association with cardiac damage, plaque vulnerability, microvascular obstruction, and cardiovascular events. Plaque vulnerability will be explored by optical coherence tomography, while microvascular obstruction will be assessed by bolus thermodilution and cardiac magnetic resonance. Participants will be followed up for 1-year to evaluate whether the presence and the burden of MNPs will be associated with a higher incidence of the cardiovascular events.",[85,26,27,31],"ST-elevation Myocardial Infarction (STEMI)",[87,26,27,88,89,90,91,59,92,93,94,95,96],"STEMI","Inflammation","OCT","Plaque composition","cardiac magnetic resonance","Exposome","Infarct Size","Coronary Microvascular Dysfunction","IMR","MRR","2025-05-01",{"date":99,"type":36},"2025-05-11",{"date":101,"type":36},"2025-04-22",{"date":103,"type":20},"2027-12-31",{"name":42,"class":43},10,{"id":107,"slug":108,"hasResults":11,"nctId":109,"briefTitle":110,"officialTitle":110,"acronym":111,"eligibilityCriteria":112,"healthyVolunteers":113,"sex":16,"minAge":114,"maxAge":115,"enrollmentInfo":116,"targetDuration":4,"studyType":117,"phases":118,"briefSummary":120,"conditions":121,"keywords":127,"overallStatus":142,"whyStopped":4,"lastUpdateSubmitDate":143,"lastUpdatePostDateStruct":144,"startDateStruct":145,"completionDateStruct":147,"leadSponsor":149,"locationsCount":4},"100588270","analysis-of-new-materials-and-artificial-turf-products-influence-and-impact-on-athlete-performance-and-perception-100588270","NCT06939218","Analysis of New Materials and Artificial Turf Products: Influence and Impact on Athlete Performance and Perception","ANMATT","Inclusion Criteria: Gender: Male or female football players. Experience: Players who have played football for at least one full season prior to participating in the study.\n\nPlaying Level: Players who have played at the base or amateur level for at least 6 years.\n\nHealth Status: Players who do not have active or chronic injuries that could affect their ability to perform performance tests.\n\nWillingness to Participate: Players who are willing to undergo performance tests and complete perception questionnaires.\n\nRecent Injury History: Players who have not experienced significant injuries in the three months prior to the start of the study.\n\nMedical Conditions: Players who do not have pre-existing medical conditions that could affect their ability to perform performance tests or endanger their health during the tests.\n\nMedication: Players who are not taking medications that could affect their ability to perform performance tests.\n\nConsent: Players who have signed an informed consent form to participate in the study and are willing to consistently follow the study protocols.\n\nAge: Players between 20 and 30 years old (to obtain a more homogeneous sample). -\n\nExclusion Criteria: Recent Injury: Players who have experienced a significant injury in the last three months that required medical attention or could affect their ability to perform performance tests.\n\nChronic Illness: Players who have a chronic illness that could affect their ability to perform performance tests.\n\nMedication: Players who are taking medications that could affect their ability to perform performance tests or could affect their understanding of the questionnaires and perception tools.\n\nMedical History: Players who have a history of cardiovascular, pulmonary, or neurological disease.\n\nRecent Surgery: Players who have had major surgery in the last six months that could affect their ability to perform performance tests.\n\nProtocol Compliance: Players who are not willing or able to consistently follow the study protocols.\n\nDisability: Players who have a physical or cognitive disability that could affect their ability to perform performance tests.\n\nConsent: Players who have not signed an informed consent form to participate in the study.\n\nAge: Players who do not meet the minimum and maximum age requirements to be included in the study.\n\n\\-",true,"20 Years","30 Years",{"count":54,"type":20},"INTERVENTIONAL",[119],"NA","This request pertains to a series of related projects on a common theme. Specifically, this set of projects aims to analyze the impact of new alternatives in materials and structures of artificial turf on athlete performance and perception, within the context of the elimination of microplastics as per Commission Regulation (EU) 2023\u002F2055 of September 25, 2023. Third-generation sports artificial turf is notable for including performance infill (granules) that provide the necessary functionality and safety for sports practice. The vast majority of fields worldwide use materials that do not comply with the new European regulation, which has granted an eight-year moratorium. Therefore, there is little time to find new alternatives. The challenge lies not only in developing new structural solutions but also in understanding their impact on athletes. This issue is of high severity, as these sports facilities are the largest in terms of space and host the highest number of Physical Activity and Sports practitioners in Europe (mainly Football, Rugby, Hockey, and Padel).\n\nFor this reason, over the past year, the IGOID Group has requested various projects to cover all the necessary phases and nuances to address this issue.\n\nThe activities included in these projects are divided into two phases:\n\nPhase 1: Evaluation of Sports Surfaces in the Laboratory (durability and surface-player and surface-ball interaction). Tests will be conducted on artificial turf samples constructed with SBR rubber (the main material to be replaced under the EU regulation), natural-origin infills, polymeric infills larger than 5 mm, and other infills. Initially, a market analysis and classification will be carried out, followed by laboratory tests. Across all projects, a minimum of 30 alternatives are expected to be analyzed.\n\nPhase 2: Field Study. Tests will be conducted on a sample of athletes on constructed surfaces representing the different alternatives evaluated in Phase 1. Performance tests and a battery of assessments will be carried out to understand athlete perception. A sample of 30 athletes will be randomly divided into groups to perform different repetitions of the test batteries, covering a minimum of six different sports facilities.",[122,123,124,125,26,126],"Artificial Turf","Athletic Performance and Injury Risk","Physical Fitness","Sports Equipment","Healthy",[122,128,124,125,26,129,130,131,132,133,134,135,136,137,138,139,140,141],"Athletic Performance","Environmental Impact","Athlete Perception","Field Studies","Laboratory Testing","Synthetic Materials","Natural Materials","Polymer Infills","Durability","Safety","Functional Performance","Regulation Compliance","Third-Generation Turf","Football (Soccer)","NOT_YET_RECRUITING","2025-04-14",{"date":101,"type":36},{"date":146,"type":20},"2025-09-01",{"date":148,"type":20},"2026-06-30",{"name":150,"class":43},"University of Castilla-La Mancha",{"id":152,"slug":153,"hasResults":11,"nctId":154,"briefTitle":155,"officialTitle":156,"acronym":4,"eligibilityCriteria":157,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":158,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":160,"conditions":161,"keywords":164,"overallStatus":142,"whyStopped":4,"lastUpdateSubmitDate":170,"lastUpdatePostDateStruct":171,"startDateStruct":173,"completionDateStruct":175,"leadSponsor":177,"locationsCount":179},"100562477","microplastics-in-the-human-respiratory-system-100562477","NCT06603675","Microplastics in the Human Respiratory System","Detection and Analysis of Microplastic Subtypes in the Human Respiratory System.","Inclusion Criteria:\n\n* patients undergoing surgery for lung cancer, emphysema, interstitial lung diseases, or other respiratory conditions,\n* patients undergoing lung transplantation (lungs removed from transplant recipients),\n* age 18 years or older,\n* ability to provide informed consent.\n\nExclusion Criteria:\n\n* patients with a history of recent or ongoing chemotherapy, immunotherapy, or radiation therapy,\n* inability or unwillingness to provide informed consent,\n* previous lung surgeries,\n* insufficient tissue or blood samples available for analysis due to technical or procedural reasons.",{"count":159,"type":20},100,"Environmental pollution from plastics has become a significant global issue, with microplastics-tiny particles resulting from plastic degradation-being increasingly detected in various environments, including aquatic ecosystems, soil, and air. These particles can enter the human body through ingestion or inhalation. Despite growing concerns, little is known about the prevalence and types of microplastics in human lungs. Some studies suggest that microplastics may negatively impact respiratory function and lead to lung diseases. Hypothetically, they could cause inflammation, metabolic disorders, and contribute to lung cancer development. However, research is still in its early stages, and conclusive evidence about the mechanisms linking microplastics to negative health effects is lacking. This study aims to quantify and characterize microplastics in the lung parenchyma and lymph nodes of patients with lung cancer and other respiratory diseases. Tissue samples will be collected during surgeries, and microplastic particles will be detected using FTIR microspectroscopy. The research may contribute to a better understanding of the role of microplastics in the development of respiratory diseases.",[26,162,163],"Lung Cancer (NSCLC)","Lung Transplantation",[165,166,167,168,169],"microplastics","lung","respiratory system","lung cancer","transplantation","2024-10-01",{"date":172,"type":36},"2024-10-03",{"date":174,"type":20},"2024-09-30",{"date":176,"type":20},"2026-07-31",{"name":178,"class":43},"Wielkopolskie Centrum Pulmonologii i Torakochirurgii",1]